Novel Immune Therapies for Renal Cell Carcinoma Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Axes
Saad E, Saliby R, Labaki C, Xu W, Viswanathan S, Braun D, Bakouny Z. Novel Immune Therapies for Renal Cell Carcinoma Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Axes. Hematology/Oncology Clinics Of North America 2023, 37: 1027-1040. PMID: 37391289, DOI: 10.1016/j.hoc.2023.05.023.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsCarcinoma, Renal CellHumansImmunotherapyKidney NeoplasmsNeoplasm Recurrence, LocalProgrammed Cell Death 1 ReceptorT-Lymphocytes, CytotoxicConceptsRenal cell carcinomaCell carcinomaMetastatic renal cell carcinomaCell death protein 1Programmed Cell Death Protein 1Novel immune targetsDeath protein 1Novel immune therapiesNovel immunotherapiesImmune therapyClinical evidenceImmune targetsImmune systemInhibitory stimuliTumoral cellsProtein 1ImmunotherapyPatientsCarcinomaImmunosuppressionTherapy